<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T17:47:41Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/53866" metadataPrefix="mods">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/53866</identifier><datestamp>2025-02-20T12:41:52Z</datestamp><setSpec>com_10324_32522</setSpec><setSpec>com_10324_952</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_32523</setSpec></header><metadata><mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:namePart>Merino Antolín, Beatriz</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Casanueva Álvarez, Elena</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Quesada, Iván</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>González Casimiro, Carlos Manuel</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Fernández Díaz, Cristina María</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Postigo Casado, Tamara</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Leissring, Malcolm A.</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Kaestner, Klaus H.</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Perdomo Hernández, Germán</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Cózar Castellano, Irene</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2022-07-06T09:00:40Z</mods:dateAvailable>
</mods:extension>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2022-07-06T09:00:40Z</mods:dateAccessioned>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2022</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="citation">Diabetologia volume 65, 2022, pages 1375–1389</mods:identifier>
<mods:identifier type="issn">0012-186X</mods:identifier>
<mods:identifier type="uri">https://uvadoc.uva.es/handle/10324/53866</mods:identifier>
<mods:identifier type="doi">10.1007/s00125-022-05729-y</mods:identifier>
<mods:identifier type="publicationtitle">Diabetologia</mods:identifier>
<mods:identifier type="essn">1432-0428</mods:identifier>
<mods:abstract>Aims/hypothesis Type 2 diabetes is characterised by hyperglucagonaemia and perturbed function of pancreatic glucagon secreting alpha cells but the molecular mechanisms contributing to these phenotypes are poorly understood. Insulin-degrading&#xd;
enzyme (IDE) is present within all islet cells, mostly in alpha cells, in both mice and humans. Furthermore, IDE can degrade&#xd;
glucagon as well as insulin, suggesting that IDE may play an important role in alpha cell function in vivo.&#xd;
Methods We have generated and characterised a novel mouse model with alpha cell-specific deletion of Ide, the A-IDE-KO&#xd;
mouse line. Glucose metabolism and glucagon secretion in vivo was characterised; isolated islets were tested for glucagon and&#xd;
insulin secretion; alpha cell mass, alpha cell proliferation and α-synuclein levels were determined in pancreas sections by&#xd;
immunostaining.&#xd;
Results Targeted deletion of Ide exclusively in alpha cells triggers hyperglucagonaemia and alpha cell hyperplasia, resulting in&#xd;
elevated constitutive glucagon secretion. The hyperglucagonaemia is attributable in part to dysregulation of glucagon secretion,&#xd;
specifically an impaired ability of IDE-deficient alpha cells to suppress glucagon release in the presence of high glucose or&#xd;
insulin. IDE deficiency also leads to α-synuclein aggregation in alpha cells, which may contribute to impaired glucagon secretion&#xd;
via cytoskeletal dysfunction. We showed further that IDE deficiency triggers impairments in cilia formation, inducing alpha cell&#xd;
hyperplasia and possibly also contributing to dysregulated glucagon secretion and hyperglucagonaemia.&#xd;
Conclusions/interpretation We propose that loss of IDE function in alpha cells contributes to hyperglucagonaemia in type 2&#xd;
diabetes</mods:abstract>
<mods:language>
<mods:languageTerm>eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">info:eu-repo/semantics/openAccess</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by/4.0/</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">© The Author(s) 2022</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">Atribución 4.0 Internacional</mods:accessCondition>
<mods:titleInfo>
<mods:title>Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods></metadata></record></GetRecord></OAI-PMH>